Pharmaceuticals Biotechnology and Life Sciences
featured
SAN FRANCISCO, May 21- Amazon.com Inc has been given a security clearance by the U.S. government that will make it easier for federal agencies to use its cloud computing services. The accreditation covers all AWS data centers in the United States, the company said on Tuesday.
» Read More
More
-
Financial pain and physical pain may be linked: A new study says people who make less money and work in blue-collar jobs are more prone to be in pain.
-
Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.
-
Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
-
U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares plunging more than 10 percent.
-
Wall Street’s on the edge of its seat ahead of Wednesday’s interest-rate announcement. You should be on the phone with your broker.
-
Amgen Inc., the world's largest biotechnology company, reported earnings of $1.12 per share on first-quarter revenues of $3.6 billion on Thursday, beating most Wall Street expectations on cost-cutting measures.
-
Schering-Plough, whose shares have been battered this year by a failed trial of its Vytorin cholesterol drug, reported a smaller-than-expected drop in quarterly earnings on Wednesday thanks to cost controls.
-
Merck and Eli Lilly reported earnings today, and CNBC asked the pharmaceutical companies’ chief executives and an analyst to discuss the results and the sector as a whole.
-
Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
-
Genentech reported earnings that edged forecasts, but sales of all four of its big brand-name drugs fell short of forecasts.
-
Genentech stock is on a tear this year and analysts are expecting double-digit sales growth for most of the biotech's key drugs this quarter. Can Genentech keep it up?
-
Takeda Pharmaceutical said it would buy U.S. firm Millennium Pharmaceuticals for $8.8 billion to boost its cancer drug business, in the biggest overseas acquisition by a Japanese drug maker.
-
He's expecting a full recovery – and more – for this company.
-
Pfizer and Nektar Therapeutics said Wednesday clinical trials of the inhaled insulin Exubera found increased cases of lung cancer, leading Nektar to end talks with potential partners to market the product.
-
CEO Fred Hassan updates investors on his company's plans to rebound from the Vytorin debacle.
-
Options activity is picking up in Johnson & Johnson stock. Why?
-
Your kid is bulging. His name is Mark. He doesn't want to talk about the past. He forgets the English language. He starts misremembering things. You suspect he might be up to something. So what do you do? Until now, your options would be limited.
-
Walgreen posted a 4.4 percent increase in sales at stores open at least a year as strong demand for Easter merchandise helped offset tepid sales growth for prescription drugs.
-
Pfizer said on Tuesday it was halting a late stage study of its experimental drug for advanced melanoma after data showed it was no better than standard chemotherapy.
-
A drug commonly used to fight AIDS appears to nearly double the risk of a heart attack, researchers said Tuesday.